Tampere University Cell Technology Master's Thesis Guide: BBT.OPN.002, BBT.MJS.109 and Trepo

Quick answer: what is the Cell Technology thesis route?

Tampere University’s Cell Technology specialization belongs to the 120 ECTS Master’s Programme in Biomedical Technology and awards Master of Science in Natural Sciences. The current programme object is BMTM.CT Cell Technology, at least 120 ECTS; this label describes the study object and is not added on top of the 120-credit degree. The current Natural Sciences thesis route uses BBT.MJS.109 Thesis Seminar, 2 ECTS, pass/fail and BBT.OPN.002 Master´s Thesis, Natural Sciences, 30 ECTS, graded 0-5. A separate BBT.OPN.EXT.002 Research Associated with MSc Thesis, 10 ECTS, pass/fail can support laboratory, computational or clinical-data research when it is defined with the supervisor, but it is not the thesis itself and should not be reported as making the thesis 40 ECTS.

1. Keep the Natural Sciences route separate from MSc (Technology)

Cell Technology is not the engineering Biomaterials and Tissue Engineering programme even though the fields overlap. The degree title, thesis course and assessment route are different. Use BBT.OPN.002 and BBT.MJS.109 as the current Natural Sciences thesis anchors. Shared tissue-engineering, biomaterials, imaging or microtechnology courses can provide scientific context, but they do not transfer MSc (Technology) administrative rules into Cell Technology. This distinction matters when planning credits, maturity requirements, seminar participation and the final thesis record in Sisu.

2. BMTM.CT describes the specialization, not extra credits

Current BMTM.CT is labelled at least 120 credits and focuses on human development, tissue biology, cell technologies and especially human stem-cell-based applications. Read that label as the programme-level study object within the 120 ECTS degree. Do not calculate 120 ECTS of BMTM.CT plus another 30 ECTS thesis. For your personal plan, confirm the exact module nesting and optional/elective choices in Sisu. The safe public facts are the 120 ECTS degree, the BMTM.CT programme object and the separately defined Natural Sciences thesis course.

3. BBT.INT.802 gives Cell Technology an explicit laboratory orientation

Current BBT.INT.802 Orientation and Study Planning has a completion method explicitly compulsory for Cell Technology and Molecular Biology students. It combines programme sessions, laboratory work, joint introductory teaching, library/information-searching training and personal study planning with a supervising teacher. This is useful context for thesis preparation because Cell Technology is laboratory intensive, but BBT.INT.802 is not the thesis seminar. Its role is earlier orientation, study planning and laboratory readiness; BBT.MJS.109 remains the thesis seminar.

4. BBT.MJS.109 is the 2 ECTS thesis seminar

BBT.MJS.109 Thesis Seminar, Natural Sciences is 2 ECTS and pass/fail. The seminar expects two presentations: first the thesis plan and later the results. Discussion covers research background, specific aims, methods, interpretation, conclusions and possible future directions. Library training on scientific information acquisition is also included. Use the seminar as a recurring quality gate: if you cannot explain the experimental unit, controls, biological model and evidence boundary clearly to peers, those elements are probably not yet clear enough in the thesis plan.

5. BBT.OPN.002 is the 30 ECTS thesis and is graded 0-5

BBT.OPN.002 Master´s Thesis, Natural Sciences is 30 ECTS and graded 0-5. It explicitly supports supervised experimental or computational research and requires a scientific written report. Before starting, the project plan must be accepted by the professor responsible for the MSc specialisation. The course also requires a maturity examination. This means a Cell Technology thesis can be wet-lab dominant, computationally assisted or, where scientifically appropriate, computational, but the biological question and evidence chain must remain explicit.

6. The optional 10 ECTS research unit stays separate

BBT.OPN.EXT.002 is a separate 10 ECTS pass/fail course for MSc-thesis-associated research such as laboratory work, computational work or clinical-data acquisition. Current public guidance says it must be defined during initial thesis planning with the supervisor and its connection to the thesis described in the thesis plan. Do not assume it is compulsory simply because Cell Technology is laboratory oriented. If it appears in your Sisu plan, treat it as a separate research activity and keep the assessed thesis credit value at 30 ECTS.

7. Start with a bounded biological claim

A strong Cell Technology thesis begins with a claim that can be tested in the available biological model. “Improve regeneration”, “differentiate stem cells” or “create a tissue model” is too broad. State the cell type or tissue model, intervention or condition, measurable endpoint and evidence level. For example, you may test whether a defined culture condition changes a specific differentiation marker and a functional readout over a stated period. The conclusion should remain at that level unless additional evidence supports a broader claim.

8. Cell source and identity are first-class variables

Cell source is not background trivia. Record the cell line, donor class or derivation context at the level required to interpret the experiment. If different donors, clones or lines are combined, decide whether they are biological replicates, separate strata or exploratory comparisons. Where identity matters to the claim, follow the host laboratory’s approved authentication and provenance practices. A high number of wells does not compensate for testing only one biological source.

9. Passage, culture history and batch effects can change phenotype

Passage number, time in culture, thawing history, confluence, media lots and operator/day effects can alter cell behaviour. Track them when they are relevant and balance comparison groups across batches where practical. If one condition was run on one day and another on a different day, the treatment effect may be confounded with day or batch. Do not hide this in the methods; either control it experimentally or acknowledge the limitation.

10. Stem-cell state, commitment and maturation are different claims

For stem-cell work, separate evidence for pluripotency, lineage commitment, differentiation markers and mature function. A marker panel may support a differentiation-state claim without proving that the cells reproduce the mature physiology of the target tissue. If the thesis claims functional maturation, include a functional endpoint appropriate to the tissue and justify why it supports that claim. If functional evidence is unavailable, narrow the wording instead of over-interpreting molecular markers.

11. Differentiation protocols must be reproducible

Document starting cell state, seeding density, matrix or coating, medium composition, key supplements, timing of changes, duration and endpoint criteria when they influence differentiation. If a protocol was adapted during the project, distinguish optimisation runs from the final evaluation. This prevents the final thesis from presenting a moving protocol as if it were one stable method.

12. Biological and technical replicates are not interchangeable

Technical replicates estimate measurement or within-preparation variability; biological replicates support claims across independent biological preparations. Multiple wells from one differentiation batch, multiple images from one organoid or repeated instrument readings from one sample are not automatically independent biological units. Define the experimental unit before analysis and ensure the statistical model reflects nesting where necessary.

13. Controls should test the exact mechanism or assay claim

Choose controls because they make the proposed inference possible. Depending on the experiment, this can include untreated, vehicle, positive, negative, reference-cell, matrix-only or process controls. State what each control is expected to demonstrate. If a positive or negative control fails, do not continue as though the experiment is unaffected; explain what can and cannot still be interpreted.

14. Microscopy needs an acquisition and sampling audit trail

Microscopy is powerful but easy to bias. Record acquisition settings, field-selection rules, magnification and processing steps that affect interpretation. If images are quantified, document segmentation, thresholds, region-of-interest rules and exclusions. Avoid choosing only visually impressive fields. A representative image should illustrate a quantified result, not replace systematic sampling.

15. Flow cytometry and high-content assays need explicit gating logic

For flow cytometry or similar single-cell measurements, document controls, compensation where applicable, gating hierarchy, excluded events and the biological unit used for statistics. Percentage-positive cells, fluorescence intensity and cell counts answer different questions. If thresholds are selected after viewing the result, disclose that decision and test whether reasonable alternatives change the conclusion.

16. Gene and protein measurements support different inference levels

Gene expression indicates transcript-level changes; protein assays add another layer; neither automatically demonstrates functional tissue behaviour. Define normalization, reference genes or controls and the reason for the selected marker panel. If RNA and protein results disagree, treat the disagreement as a biological or technical finding to investigate rather than selectively reporting the preferred layer.

17. Tissue and organoid models have bounded biological scope

Organoids, engineered tissues and other in-vitro models can reproduce selected structures, pathways or functions without recreating an entire human organ. Describe model composition, developmental or culture stage, missing cell types or environmental factors and the function actually measured. Discussion can address translational relevance, but the conclusion should not silently jump from an in-vitro model to clinical effectiveness.

18. Tissue engineering is relevant, but not every Cell Technology thesis needs a scaffold

Current Cell Technology focuses on tissue biology and tissue engineering, and Tampere’s current tissue-engineering courses provide useful methodological context. Still, a thesis may study cells without a scaffold or material intervention. If biomaterials are used, define composition, surface or matrix state and the cell-material interaction relevant to the hypothesis. Avoid treating “biocompatible” as a universal property detached from cell type, exposure and endpoint.

19. Dose, exposure and time-course studies need biological rationale

For drugs, growth factors, cytokines, coatings or environmental perturbations, justify concentration range, exposure duration and sampling times. Use appropriate vehicle or process controls. A single high dose may demonstrate a response but say little about biological relevance. If many doses or time points are tested, define primary comparisons and address multiplicity in the analysis.

20. Statistics should follow the experiment’s hierarchy

Plan analysis from the true independent units. Images may be nested within wells, wells within differentiation batches and batches within donors. Standard tests that ignore this structure can exaggerate certainty. Report sample sizes at each level, effect sizes and uncertainty where appropriate. With few donors or biological preparations, state that population-level generalisation remains limited even if thousands of cells were measured.

21. Human-derived material requires approvals before use

Human cells, tissues, patient-derived samples or participant-linked information can trigger ethics, consent, permission and data-governance requirements. Resolve the applicable route with the supervisor and host research organisation before collection or use. Material already stored in a laboratory is not automatically authorised for a student thesis. The public manuscript should include only the information needed to understand the research.

22. Pseudonymised biological data may still be personal data

If coded samples or datasets can be linked back to individuals, they are not automatically anonymous. Define who controls the re-identification key, what identifiers the student can access, where data are stored, who can access them and what can appear in the public thesis. Follow Tampere’s current student data-protection instructions rather than relying on informal laboratory conventions.

23. Animal work stays inside approved institutional procedures

If an existing Cell Technology project involves animals or animal-derived experimental work, the thesis should operate inside the approved research project, supervision and legal framework. A thesis guide is not a substitute for animal-research training, licences or institutional procedures. Report the approved model and the methods necessary to evaluate the scientific claim without inventing operational protocols from secondary sources.

24. Laboratory safety and contamination control are part of method quality

Cell culture, biological material, chemicals and shared instruments require host-laboratory training and safety procedures. Contamination, cell misidentification or major protocol failure can invalidate the biological conclusion. Follow the research group’s approved practices for contamination control, waste handling, equipment use and biosafety. In the thesis, report the scientific controls and quality checks that affect interpretation rather than turning the manuscript into an operational safety manual.

25. Reproducibility requires sample-to-figure traceability

Build an evidence trail from cell or tissue identifier to culture batch, reagent lot, instrument or microscope raw file, processed dataset, analysis script and final figure. Preserve software and image-analysis versions when they matter. This is especially important in long projects where protocols evolve and several differentiation batches are analysed. A final figure should be traceable to the exact biological material and processing steps that produced it.

26. Separate method development from final evaluation

Cell Technology projects often include optimisation: changing coatings, media, timing, imaging settings or analysis thresholds. That is legitimate, but label development data separately from the data used to support the final thesis claim. If the final method was selected after inspecting earlier results, explain the selection process. This distinction prevents exploratory optimisation from being presented as if it were a pre-specified confirmatory experiment.

27. Translational claims need an evidence ladder

Use explicit labels for evidence level. A cell assay can support a cell-response claim; an engineered tissue can support a model-level functional claim; preclinical or clinical claims require corresponding evidence. Human stem-cell-based applications can have obvious regenerative-medicine relevance, but future therapeutic potential is not the same as demonstrated safety or efficacy. Strong discussion sections make this boundary visible.

28. AI use must preserve scientific accountability and data protection

Tampere’s current AI guidance keeps responsibility with the student. AI may assist with language, coding or idea generation when allowed, but verify literature summaries, citations, code and biological explanations against primary sources and data. Do not upload confidential research data, unpublished partner material, participant information or protected biological datasets to external AI services without an approved basis. Follow any thesis-specific acknowledgement instructions agreed with the supervisor.

29. Write methods and results while experiments are running

Long cell-culture projects are difficult to reconstruct retrospectively. Write method versions, culture timelines and analysis decisions as they occur. Maintain a result ledger connecting each figure to the research question, biological batch and raw data. In Results, report observations without turning every sentence into interpretation. In Discussion, explain mechanism, limitations, conflicting evidence and what the experiment cannot establish.

29A. Build a cell-state and assay evidence matrix

A Cell Technology thesis becomes much easier to defend when every cell claim is mapped to the exact cell population and assay that supports it. Create a cell-state matrix with one row for each relevant cell population: starting cell source, stem-cell state, intermediate cell state, differentiated cell state and, where applicable, mature functional cell state. For each cell row, record the cell identifier or donor/clone, cell passage or culture age, cell batch, cell density, cell matrix or coating, cell-medium condition, cell-treatment condition and cell-assay endpoint. This makes it obvious when two figures that appear to describe the same cell biology actually come from different cell batches or different cell states.

Then add an assay-evidence column. A cell-viability assay supports a bounded cell-viability claim; a cell-proliferation assay supports a proliferation claim; a cell-marker panel supports the stated molecular or phenotypic cell markers; a cell-morphology image supports morphology; a cell electrophysiology, contraction, secretion or other functional assay may support a functional cell claim. Do not use one cell assay as a substitute for another. In stem-cell work, the matrix should distinguish stem-cell maintenance, stem-cell differentiation, lineage-specific cell markers and mature cell function. In tissue models, distinguish individual cell evidence from multicellular or tissue-level evidence.

Use the same matrix to audit replication. Mark whether each cell result comes from independent donors, independent cell lines, independent clones, independent differentiation batches, repeated cell-culture wells or repeated cell images. Only the appropriate biological unit should drive inferential statistics. Also record cell exclusions, failed cell batches and contamination-related exclusions. If a Cell Technology conclusion depends on one cell line, one donor, one differentiation or one cell batch, say so explicitly. The purpose is not to repeat the word cell; it is to force every Cell Technology claim back to a traceable biological cell state, assay and replicate structure.

30. Maturity, originality, Trepo and publicity are separate gates

BBT.OPN.002 requires a maturity examination. Follow the current Tampere maturity route applicable to your prior language demonstration. The thesis process also includes originality checking; complete the current Turnitin/plagiarism-detection workflow with supervisor permission before final submission. The finished thesis is public, so keep confidential or identifiable material outside the public manuscript where required. Submit the final valid PDF/A to Trepo and allow time for examination before the intended graduation date.

31. Examination and timing should be planned backwards

The current thesis course is graded 0-5, while BBT.MJS.109 and BBT.OPN.EXT.002 are pass/fail. Keep these assessment objects separate. Tampere’s university-wide guidance gives a normal examiner period of 21 days, potentially 28 days when an additional maturity test is required. That period is not the whole graduation timeline: preliminary review, corrections, originality checking, Trepo submission and faculty processing can add time. Work backwards from the graduation deadline instead of submitting the thesis at the last possible moment.

For the Cell Technology Natural Sciences route, do one final credit-object audit before graduation: BBT.OPN.002 remains the 30 ECTS assessed thesis, BBT.MJS.109 remains the 2 ECTS pass/fail seminar, and BBT.OPN.EXT.002 remains the separate 10 ECTS pass/fail thesis-associated research unit when it is part of the applicable plan. The optional 10 ECTS research can be highly relevant to a Cell Technology laboratory project, but relevance is not the same as universal compulsory status. Confirm the actual Sisu placement with the supervisor or programme instructions rather than converting the 30 ECTS thesis into a 40 ECTS thesis by arithmetic.

A final stem-cell evidence audit is equally important. In Cell Technology, human stem-cell-based applications are central to the programme, but a stem-cell result must still identify whether the evidence concerns maintenance of stem-cell state, lineage commitment, differentiation markers, morphology, molecular phenotype or functional maturation. If a tissue model or stem-cell-derived system is used, state exactly what biological function was measured and what important features of the target tissue are absent. This keeps the Natural Sciences route scientifically ambitious without allowing Cell Technology’s translational context to outrun the evidence.

For the final evidence audit, create a table with one row per major claim and columns for biological unit, experiment or dataset, assay/measurement, preprocessing, statistical test or model, uncertainty estimate, figure/table and limitation. This makes hidden dependencies visible: for example, a statement about improved differentiation may rely on only one donor, one marker, one time point or one differentiation batch. If the claim cannot be mapped to a defined evidence row, either add the missing evidence or narrow the wording. Repeat the same audit for translational language: identify every sentence containing terms such as therapeutic, regenerative, safe, functional, patient-relevant or clinically useful and verify that its evidence level is clearly labelled.

A second audit should focus on reproducibility across batches. Ask whether another trained researcher could identify the exact cells or tissue model, reconstruct culture history, obtain the relevant reagent and matrix information, locate raw microscopy or instrument files, run the analysis and understand every exclusion. Where proprietary or privacy constraints prevent full disclosure, state the constraint and preserve the internal traceability needed for supervision and examination. This balance - public scientific clarity without exposing protected information - is especially important for collaborative biomedical research.

32. Final Cell Technology checklist

Before starting, verify BMTM.CT, BBT.MJS.109, BBT.OPN.002, your BBT.INT.802 completion method and whether BBT.OPN.EXT.002 appears in your personal Sisu plan. Confirm the accepted project plan, supervisor, laboratory or data access, ethics/permissions, biological model, experimental unit, controls, primary outcomes and fallback scope. Before submission, verify sample-to-figure traceability, donor/batch/passages, image or cytometry analysis, statistics, evidence-level wording, protected-data handling, AI acknowledgement, seminar, maturity, originality check, PDF/A, Trepo and examiner timing. A strong Cell Technology thesis is not the project with the most assays; it is the project whose biological claim stays traceable from the model and raw evidence to the final conclusion.